DDReg Knowledge Capsule

ตอน

• 
  Global Biosimilar Pathways 2026 : US, EU, UK & Asia 24.09.2026 18นาที

  Welcome to the DDReg Knowledge Capsule!In this episode, we unpack the rapidly changing global regulatory landscape for biosimilar development across key target markets: the US (FDA), European Union (EMA), UK (MHRA), China (NMPA/CDE), and Japan (PMDA).We examine the pivotal 2026 transition away from routine comparative clinical efficacy trials toward tailored, risk-based evaluation frameworks grounded in high-resolution comparative analytical data, pharmacokinetic (PK) studies, and immunogenicity assessments.Key topics covered in this episode:Tailored Evidence Pathways: How regulators like the FDA, EMA, MHRA, and PMDA are evaluating biosimilarity without automatically requiring comparative efficacy studies.Reference Product Selection & Bridging: Navigating jurisdiction-specific reference rules and establishing scientific bridging between foreign comparators and local originators.Global Core Strategy: Designing one unified scientific dossier with planned regional adaptations to avoid duplicated clinical trials and submission delaysVisit our blog - https://resource.ddregpharma.com/blogs/global-biosimilar-regulatory-strategy/
• 
  Registering Biosimilar Drugs with Health Canada 23.09.2026 11นาที

  Welcome to DDReg Knowledge Capsule! In this episode, we explore Health Canada's regulatory framework for registering biosimilar biologic drugs. We break down the fundamental differences between biosimilars and generic small-molecule drugs, explain why biosimilars are authorized through the New Drug Submission (NDS) pathway, and discuss the pivotal role of the Canadian Reference Biologic Drug (CRBD). Listeners will also gain actionable insights into scientific reviews by the Biologic and Radiopharmaceutical Drugs Directorate (BRDD), indication extrapolation requirements, and post-market pharmacovigilance obligationsCheck out our blog - https://resource.ddregpharma.com/blogs/biosimilar-registration-in-canada-guide/
• 
  Global Regulatory Operating Model For Pharma Leaders 18.09.2026 21นาที

  This episode explores how pharmaceutical organisations can effectively structure regulatory roles across global, regional, and local markets. Based on the DDReg guide to global regulatory operating models, the discussion highlights the strategy of "controlled decentralization"—maintaining global consistency for core scientific positions while ensuring local authority ownership where jurisdiction-specific knowledge is critical.Key topics covered include:The five-layer operational structure: Defining decision rights across enterprise regulatory governance, product strategy, regional translation, local execution, and regulatory operations.Cross-functional coordination: Clarifying accountabilities between regulatory affairs, clinical development, CMC/quality, pharmacovigilance, and supply chain functions.Modern data standards & technology: How eCTD v4.0, ISO IDMP master data standards, Regulatory Information Management (RIM) systems, and AI in 2026 are reshaping regulatory workflows and data governance
• 
  Mastering Global CMC Variations & Life Cycle Management 11.09.2026 22นาที

  Welcome to DDReg Knowledge Capsule! In this episode, we dive into the complex world of global post-approval change management in the pharmaceutical industry.When a drug product undergoes a single internal scientific or manufacturing modification—such as a site transfer, process modification, or analytical method update—it can trigger dozens of distinct regulatory submissions across international jurisdictions. This episode explores why global pharmaceutical companies must separate the globally controlled scientific change from market-specific regulatory pathways.For more, visit our blog: https://resource.ddregpharma.com/blogs/global-variation-management-post-approval-change/
• 
  Malaysia NPRA 2026: Fast Route for Biosimilar Registration 04.09.2026 22นาที

  Welcome to the DDREG Knowledge Capsule. In this episode, we unpack the National Pharmaceutical Regulatory Agency's (NPRA) landmark 2026 reliance pilot pathway in Malaysia. We explore how eligible biosimilars with prior US FDA or EMA approval can now access an accelerated 60-working-day registration timeline.However, this rapid timeline is far from automatic. We break down the strict parameters sponsors must navigate to succeed, including the critical three-month post-approval submission window, rigorous dossier sameness requirements, and NPRA-specific local additions like ASEAN Zone IVb stability data. Tune in to discover how global biopharma teams can proactively adapt their launch strategies to successfully leverage this new pathwayFor more ready this blog - https://resource.ddregpharma.com/blogs/biosimilar-registration-malaysia-npra/
• 
  Mandatory EUDAMED Compliance for German Medical Devices 2026 31.08.2026 21นาที

  Welcome to this episode of the DDReg Knowledge Capsule. In this session, we break down Germany's critical regulatory transition from the national DMIDS database to the EU-wide EUDAMED platform. We explore the operational modules that became mandatory on 28 May 2026—including Actor Registration, UDI/Device Registration, Notified Bodies & Certificates, and Market Surveillance—and clarify the upcoming 28 November 2026 transition deadline for legacy and MDR/IVDR devices. Listeners will learn about the process for validating Single Registration Numbers (SRNs) in Germany, the special requirements for non-EU manufacturers working with authorised representatives, and how to avoid costly compliance errors like assuming automatic data migration from DMIDS.For more, visit our blogs: https://resource.ddregpharma.com/blogs/eudamed-mandatory-registration-germany-bfarm/
• 
  India's Pharma Shift from Generics to Innovation 27.08.2026 17นาที

  India is evolving from "the pharmacy of the world" to a powerhouse of pharmaceutical innovation, focusing on biosimilars, complex generics, and advanced therapies. In this episode, we unpack how this transition is fundamentally reshaping global regulatory strategies, clinical trial expectations, and FDA compliance for companies targeting international marketsVisit our blog for more: https://resource.ddregpharma.com/blogs/india-pharmaceutical-industry-innovation/
• 
  Why Gene Therapy Manufacturing Fails FDA 21.08.2026 17นาที

  Why do even the most revolutionary gene therapies with promising clinical results face critical roadblocks on their path to commercial approval? In this episode of the DDReg Knowledge Capsule, we delve deep into the core reasons behind Biologics License Application (BLA) delays, focusing on common Chemistry, Manufacturing, and Controls (CMC) pitfalls, weak analytical strategies, and limited comparability data.We unpack the regulatory expectations of the FDA’s Center for Biologics Evaluation and Research (CBER) and the Office of Therapeutic Products (OTP), highlighting why early regulatory alignment, rigorous product characterisation, and proven manufacturing consistency are absolutely vital for success. Whether you are navigating vector-related complexities, scale-up challenges, or preparing for critical pre-BLA meetings, this episode provides the strategic insights needed to ensure your manufacturing, clinical, and quality teams are fully aligned for FDA readinessRead this Blog: https://resource.ddregpharma.com/blogs/gene-therapy-bla-submission-regulatory-strategy/
• 
  Navigating the UAE's MOHAP to EDE Transition 16.08.2026 20นาที

  Welcome to the DDReg Knowledge Capsule. In this episode, we unpack the historic shift in the UAE’s healthcare regulatory framework as the Emirates Drug Establishment (EDE) takes over medical device oversight from the Ministry of Health and Prevention (MOHAP). Established under Federal Decree-Law No. 38 of 2024, the EDE centralizes compliance across all seven emirates. We discuss critical updates for manufacturers and distributors, from key technical dossier requirements (such as CE Marks and FDA clearances) to the new 45-working-day completion timeline and the 5-year marketing authorization validity. Tune in to discover how to align your regulatory strategy and secure faster access to the UAE market.https://resource.ddregpharma.com/blogs/uae-mohap-to-ede-transition-medical-devices-regulations/
• 
  Jordan Joins PICS Pharmaceutical Inspection Scheme 14.08.2026 5นาที

  Welcome to the DDReg Knowledge Capsule! In this episode, we explore the major regulatory milestone of 1 January 2026, when the Jordan Food and Drug Administration (JFDA) became the 57th Participating Authority of the Pharmaceutical Inspection Co-operation Scheme (PIC/S).As only the second Arab nation to achieve full PIC/S membership, Jordan is significantly boosting its standing as a reliable pharmaceutical manufacturing hub in the MENA region. We break down what this strategic shift means for manufacturers in practice—from the transition to more rigorous, risk-based inspections to elevated global GMP compliance expectations spanning quality systems, data integrity, and validation. Listen in to find out how businesses can proactively adapt to Jordan's new regulatory landscape and leverage it to secure stronger international partnerships and enhanced market accesshttps://resource.ddregpharma.com/blogs/jordan-pics-membership-gmp-compliance/
• 
  AI in Regulatory Affairs: What It Can and Can’t Do in 2026 07.08.2026 22นาที

  Welcome to the DDReg Knowledge Capsule. In this episode, we cut through the industry hype to examine exactly what AI can and cannot do in 2026. Learn why AI struggles with complex, judgment-dependent tasks like clinical risk-benefit assessments, novel product pathway determinations, and health agency negotiations. We map out a practical task classification framework—distinguishing between AI-led, AI-assisted, and strictly human-led operations—to help your team safely leverage technology without compromising compliance.For more, visit our blog - https://resource.ddregpharma.com/blogs/ai-in-regulatory-affairs/
• 
  NAFDAC Drug Registration: Nigeria Market Access Guide (2026) 31.07.2026 21นาที

  This Podcast about Nigeria has emerged as one of Africa’s most dynamic pharmaceutical markets, but for global manufacturers, the path to entry is defined by the rigorous oversight of the National Agency for Food and Drug Administration and Control (NAFDAC). In this episode, we move beyond the theory of registration to explore the operational realities of the Nigerian market.We break down the critical stages of the approval process—from pre-submission positioning and utilizing collaborative pathways for WHO-prequalified drugs to navigating the NAPAMS portal and the technicalities of GMP inspections. More importantly, we identify the specific administrative "landmines" that often derail submissions, such as the high-stakes 90-working-day query response deadline, the jurisdictional nuances of notarizing legal documents, and the common pitfalls of Superintendent Pharmacist license renewals.Whether you are an established firm or a new entrant, this session provides the strategic insights needed to avoid administrative delays, ensure import compliance, and achieve a realistic timeline for market access in NigeriaFor Detials - https://resource.ddregpharma.com/blogs/nafdac-drug-registration-nigeria/https://resource.ddregpharma.com/blogs/nafdac-drug-registration-nigeria/
• 
  The RaaS Revolution in Pharma 2026 24.07.2026 19นาที

  In this episode, we explore why pharmaceutical companies are moving away from traditional internal departments and adopting Regulatory-as-a-Service (RaaS). We break down how this agile model provides on-demand access to global regulatory expertise and advanced technology—such as AI-powered dossiers and autonomous compliance agents—while significantly reducing fixed overhead costs. Tune in to learn how RaaS is helping firms stay "always audit-ready" in a rapidly shifting global landscape
• 
  Winning Thailand FDA Priority Drug Approvals 16.07.2026 23นาที

  Welcome to the DDReg Knowledge Capsule. In this episode, we demystify the Thailand FDA Priority Review, a process that functions more as a controlled acceleration mechanism than a straightforward fast track. While many sponsors expect a simple path to market, we explore why dossier maturity, therapeutic justification, and submission coherence are the true deciders of speed.For more details - https://resource.ddregpharma.com/blogs/thailand-fda-priority-review-eligibility-timelines-accelerated-drug-approval-strategy/
• 
  Egypt EDA Drug Approval and Registration Guide 10.07.2026 19นาที

  This episode explores why Egypt is a top priority for regional expansion, boasting a pharmaceutical sector valued at approximately USD 5.9 billion.We dive into the regulatory framework established by Law No. 151 of 2019, which transitioned authority to the Egyptian Drug Authority (EDA).The discussion covers the essential 10-step authorization process, the mandatory requirement for a locally licensed agent, and the technical intricacies of the Common Technical Document (CTD) dossierRead View - https://resource.ddregpharma.com/blogs/egypt-eda-drug-approval-regulatory-framework-dossier-requirements-authorization-strategy/
• 
  Navigating TGA Australia Drug Registration and Compliance 03.07.2026 25นาที

  This episode provides a comprehensive guide to the Therapeutic Goods Act 1989, exploring the various pathways for getting prescription medicines onto the Australian Register of Therapeutic Goods (ARTG). We dive into the differences between Standard, Verification, and Priority Review pathways, while highlighting the critical importance of Australian-specific documentation, such as the Australian Specific Annex (ASA) for Risk Management Plans. Listeners will also learn how to avoid common registration pitfalls—including GMP clearance gaps and PI/CMI non-compliance—to ensure a more efficient and successful submission process.For more, visit our blog: https://resource.ddregpharma.com/blogs/tga-australia-drug-registration/
• 
  Global Orphan Drug Designations: Building a Cross-Market Strategy 30.06.2026 22นาที

  In this episode of the DDReg Knowledge Capsule, we explore the strategic importance of building a comprehensive, multi-market regulatory approach for rare disease treatments. While orphan drug frameworks in the US, EU, Japan, and Australia share the goal of incentivising development for niche populations, they differ significantly in their prevalence thresholds, eligibility criteria, and financial incentives.For more details, visit our blog: https://resource.ddregpharma.com/blogs/orphan-drug-designation-strategy/
• 
  Sri Lanka’s 2026 Medical Device Regulatory Registration 26.06.2026 21นาที

  In this episode, we explore the significant transformation of the medical device landscape in Sri Lanka under the mandate of the NMRA. We break down the risk-based classification system—from low-risk Class One items like bandages to the high-risk apex of Class Three devices like cardiac stents. Learn how international manufacturers can leverage the Global Recognition Pathway to fast-track approvals using existing Five Ten Kay clearances, M D R, or I V D R frameworks. We also dive into essential compliance requirements, including ISO thirteen four eight five quality systems and ISO fourteen nine seven one risk analysis, to help you navigate the 2026 registration process with accuracy and efficiencyFor more, visit our blog - https://resource.ddregpharma.com/blogs/medical-device-registration-in-sri-lanka/
• 
  South Korea MFDS Drug Registration: 2026 Updates and Approval Guide 15.06.2026 20นาที

  This episode explores the significant 2026 updates to the Ministry of Food and Drug Safety (MFDS) drug registration process in South Korea. We dive into the relaxation of mandatory domestic clinical trials in favour of multinational Phase 3 data, the expansion of the conditional approval pathway for innovative medicines, and the increasing alignment of biosimilar frameworks with international standards. The discussion also covers practical submission strategies using the EZDRUG system and what sponsors should expect regarding review timelines and pharmacovigilance obligations in this evolving marketFor more, visit our blog - https://resource.ddregpharma.com/blogs/mfds-drug-registration-in-south-korea/
• 
  2026 SFDA Roadmap: Mastering Pharmaceutical Registration in Saudi Arabia 12.06.2026 21นาที

  In this episode of the DDReg Knowledge Capsule, we explore the regulatory complexities of entering the Middle East’s largest pharmaceutical market, currently valued between $10.5 and $12.3 billion. We break down the SFDA’s comprehensive registration process, from the mandatory appointment of a Saudi Authorized Representative (SAR) to the technical nuances of submitting eCTD-compliant dossiers.The discussion highlights critical compliance hurdles, such as the strict requirements for Arabic labeling and the necessity of providing stability data tailored to Zone IVb climatic conditions.We also cover the typical 8 to 18-month approval timeline and the vital post-approval obligations—including pharmacovigilance and five-year renewals—required to maintain market access.This session is designed to help manufacturers transform the registration process from a bureaucratic hurdle into a strategic success